Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Dec 13;106(2):333–343. doi: 10.1038/bjc.2011.546

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2012 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Indole-3-carbinol and bortezomib cause cell cycle arrest in OVCAR3 and OVCAR5 cells. (A) OVCAR3 and (B) OVCAR5 cells were treated with I3C, bortezomib or in combination for 24 h at the indicated concentrations. Cells were fixed and stained with PI followed by flow cytometric analysis for DNA content as described in Materials and Methods. A representative DNA histogram is shown for each condition. The mean percentage of cells from a triplicate experiment is indicated for cells in G1-, S- and G2-M-phase for each condition. (C) OVCAR3 and (D) OVCAR5 cells were treated with I3C, bortezomib or in combination as in (A) and (B), respectively. Whole-cell extracts were isolated and immunoblotted with the indicated antibodies. Actin was used as a loading control.